Monopar Therapeutics Inc. Made Headway

Mon, Nov 07, 2022 at 07:51 PM

Monopar Therapeutics Inc. (MNPR:NASDAQ) soared at $3.95, representing a gain of 32.6%. On Mon, Nov 07, 2022, MNPR:NASDAQ hit a New 2-Week High of $3.95. The stock got featured on our News Catalysts scanner on Wed, Oct 19, 2022 at 11:17 AM in the 'MISCELLANEOUS' category. From Tue, Oct 25, 2022, the stock recorded 77.78% Up Days and 60.00% Green Days

About Monopar Therapeutics Inc. (MNPR:NASDAQ)

Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.

Top 10 Gainers:

Creatd Inc. (CRTD:NASDAQ), 48.39%
Arqit Quantum Inc. (ARQQ:NASDAQ), 46.87%
Bull Horn Holdings Corp. (BHSE:NASDAQ), 44.67%
Veru Inc. (VERU:NASDAQ), 39.52%
Oyster Point Pharma, Inc. (OYST:NASDAQ), 38.56%
Phunware, Inc. (PHUN:NASDAQ), 38.33%
Monopar Therapeutics Inc. (MNPR:NASDAQ), 32.55%
Funko, Inc. (FNKO:NASDAQ), 28.66%
ACM Research, Inc. (ACMR:NASDAQ), 27.69%
GigaCloud Technology Inc (GCT:NASDAQ), 26.61%